Best targeted drug plan for colon cancer with low RAS mutations
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests the best anti-EGFR drug approach for people with stage IV colon or rectal cancer whose tumor has low levels of RAS mutations. It aims to see whether this treatment works better while still keeping side effects manageable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colon or rectal cancer that has spread (stage IV) and is confirmed by tissue testing
- Your metastases cannot be fully removed by surgery (or you refuse surgery)
- Your tumor test shows a low-frequency RAS mutation (your local lab must confirm this)
- You’re age 18 or older, can do daily activities fairly well (ECOG 0–2), and can receive chemotherapy
- You have enough blood and organ function (bone marrow, liver, and kidneys) for chemotherapy
- You have at least one measurable tumor spot that can be tracked on scans, and you can provide tumor tissue for testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of chemotherapy and targeted therapy with or without adding radiation and two immunotherapy drugs for advanced rectal cancer that has spread. It looks at whether adding radiation and immunotherapy can help control the cancer better for people with certain genetic types (RAS mutation and pMMR).
This trial tests a combination of two targeted drugs (panitumumab and sotorasib) with a common IV chemo (5-fluorouracil) as a first treatment for people with a specific type of advanced colorectal cancer who cannot tolerate stronger chemo. It offers a gentler option that may be more effective than standard care.
This trial tests whether a combination of targeted radiation (SBRT), chemotherapy (CAPEOX), a biologic drug (bevacizumab), and an immunotherapy (PD-1 inhibitor) can help people with a specific type of advanced colorectal cancer that cannot be removed by surgery. It is for patients whose tumors have a RAS gene mutation and are microsatellite stable (MSS).
This trial tests a combination of two drugs—cetuximab or bevacizumab plus a chemotherapy pill (trifluridine/tipiracil)—for people with metastatic colorectal cancer that has no RAS or BRAF mutations. It's for patients whose cancer grew after first responding to cetuximab, and who have had other treatments since then.
This Phase 2 trial compares two treatment combinations as a first treatment for metastatic (spread) colon or rectal cancer. It looks to see whether one combo works better or is safer than the other.
This trial tests whether anti-EGFR therapy works better for people with left-sided colorectal cancer that has spread, whose tumors do not have certain gene mutations (RAS wild-type). It is for those who have not yet had treatment for metastatic disease.
Hear when a new Treatment Related Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.